The 2022 programme will cover advances in drug discovery in major therapeutic areas, including bacterial and viral infections, with a particular attention to current and emerging viral pandemics, but also neurodegenerative and cardiovascular diseases, rare diseases and cancer. EFMC-ISMC 2022 will also feature most recent advances in new technologies such as the exploitation of RNA as drug target, artificial intelligence in drug discovery, natural products-based drug discovery, DNA encoded libraries applications and the development of covalent drugs, PROTACs and molecular glues. Innovative approaches in medicinal chemistry will be included such as the development of immunomodulating compounds or the application of affinity selection – mass spectrometry for drug discovery. In a series of dedicated sessions, the interface between chemical biology and drug discovery will be highlighted, including topics such as in vivo chemistry for target discovery and validation, molecular imaging, and photochemical approaches. Finally, particular emphasis will again be put on first time disclosures and recent highlights in medicinal chemistry.
Date: 21st – 22nd September 2022
Location: London, UK
Advancements in extra-hepatic delivery of oligonucleotides
The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.
Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.
Benefits of attending:
•Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials
•Deepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity
• Understand the regulatory and CMC environment surrounding oligonucleotide therapeutic development
•Explore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA
•Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics
Plus, two interactive half day pre-conference workshops on 20th September 2022:
•Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator, Ritwick Sawakar, MRC Investigator, MRC Toxicology Unit, University Of Cambridge
•Managing CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala, CEO/Owner/Principal Consultant, Aurora CMC Consulting
CHAIRS FOR 2022:
•Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon
•Jimmy Weterings, Principal Scientist, AstraZeneca
FEATURED 2022 SPEAKERS INCLUDE:
•Shalini Anderson, Vice President Oligonucleotide Discovery,AstraZeneca
•Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech
•Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen pharmaceuticals
•Sarah Tabrizi,Director of UCL Huntington’s disease centre, UCL Institute of Neurology
•Macarena Hernandez-Jimenez, Chief Scientific Officer, AptaTargets
•David Evans, Chief Scientific Officer, Sirnaomics
•Eric Lim, Director, Platform, Discover Research, Stoke Therapeutics, Inc.
•Chris Chorley, Associate Director, Global Regulatory CMC, Biogen
•Oliver Ernst, Managing Director, Chief Operating Officer, Neuway Pharma GmbH
Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator
Bart Anderson, Senior Director of R&D, Exicure
Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers of:
-Novel Therapeutic Modalities
-C-level Scientific Executives
-Formulation and Drug Delivery
-Clinical Research and Development
BOOK BY 29TH APRIL AND SAVE £400
Additional Contact Info:
T: +44 (0)2 £200 0 7827 6154
LinkedIn: SMi Pharma
Twitter: @SMiPharma | #SMiOligonucleotides
FDA and EU regulations require that firms have a program for the calibration and maintenance of test and measurement equipment.
The program must include: intervals, scheduling, specific procedures, limits of accuracy/precision, and remedial action in the event that the equipment does not meet established requirements.
Conference-Service.com offers, as part of its business activities, a directory of upcoming scientific and technical meetings. The calendar is published for the convenience of conference participants and we strive to support conference organisers who need to publish their upcoming events. Although great care is being taken to ensure the correctness of all entries, we cannot accept any liability that may arise from the presence, absence or incorrectness of any particular information on this website. Always check with the meeting organiser before making arrangements to participate in an event!